Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: Difference in metabolism as a possible mechanism

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages

  Kijima, Takashi ^a   Shimizu, Tomohito ^b   Nonen, Shinpei ^c   Furukawa, Mitsugi ^d   Otani, Yasushi ^a   Minami, Toshiyuki ^a   Takahashi, Ryo ^a   Hirata, Haruhiko ^a   Nagatomo, Izumi ^a   Takeda, Yoshito ^a   Kida, Hiroshi ^a   Goya, Sho ^a   Fujio, Yasushi ^b   Azuma, Junichi ^c   Tachibana, Isao ^a   Kawase, Ichiro ^e  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d Saiseikai Senri Hospital   (Japan)

^e OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE DELETION; HUMAN; LIVER FUNCTION; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG METASTASIS; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; JAPAN; LIVER; LUNG NEOPLASMS; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSAMINASES; TREATMENT OUTCOME;

EID: 79960128400     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.3368     Document Type: Article

References (9)

1. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
2. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2009
3. Li J, Zhao M, He P, et al: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13:3731-3737, 2007 (Pubitemid 46955138)
4. Nishida Y, Fukuda T, Yamamoto I, et al: CYP2D6 genotypes in a Japanese population: Low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10:567-570, 2000
5. McKillop D, McCormick AD, Millar A, et al: Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 35:39-50, 2005 (Pubitemid 40459216)
6. Swaisland HC, Cantarini MV, Fuhr R, et al: Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 45:633-644, 2006 (Pubitemid 44046489)
7. Swaisland HC, Ranson M, Smith RP, et al: Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44:1067-1081, 2005 (Pubitemid 41356392)
8. Takeda M, Okamoto I, Fukuoka M, et al: Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. J Clin Oncol 28:e273-274, 2010
9. Seki N, Uematsu K, Shibakuki R, et al: Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol 24:3213-3214, 2006; author reply 3214-3215